Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.
about
Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United StatesSecond Korean guidelines for the management of Crohn's disease.Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis.Top-down approach to biological therapy of Crohn's disease.Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors.Adalimumab in ulcerative colitis - efficacy, safety and optimization in the era of treat-to target.Biomarkers in Search of Precision Medicine in IBD.Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease.Optimization of biologic therapy in Crohn's disease.Editorial: therapeutic drug monitoring for anti-TNF agents-has it all been said? Author's reply.Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease.Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab?Tissue Drug Concentrations of Anti-tumor Necrosis Factor Agents Are Associated with the Long-term Outcome of Patients with Crohn's Disease.Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays.A role for thiopurine metabolites in the synergism between thiopurines and infliximab in inflammatory bowel disease.Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease.Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions.Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD.Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn's disease.
P2860
Q33584629-D6AF54EF-80AA-4C60-A131-E42538C8A894Q37662498-85D15065-49EC-4EA3-A279-C34A5FB5840CQ38696735-5C1A4338-F2DF-43F4-BA77-9B34C47B83CCQ38764671-49E3E27F-6C2D-49F5-9F2F-ED652E6E333EQ38798678-D78DD3E2-6F1F-4EDA-AF01-9CB9C73B4B0EQ38895960-079D1F52-2D9B-4CC8-9287-230F500EF063Q38964878-26DC7E13-C507-48BE-BACE-F4F96C067C22Q39030608-7BB6ED6F-3971-4F80-B01F-40485D3C259CQ47389870-D09A04BB-EEDE-4671-B7D5-54B16E9EA13DQ47438989-12FB6E44-D2F8-42D2-9089-64BCCF1F93D7Q47805665-39961ED8-F726-4F2C-BFD5-FFDDE237A11CQ48192590-74E232D1-B913-472C-AB90-E869829CFF8BQ48285639-863D80C6-6A1F-4545-9548-F8EDDF314923Q48535499-AC978F4A-E8AF-41F6-892A-D7C2B198F933Q49126220-B51D8AEA-D7F7-42CB-B125-8CB636F132A8Q49960165-38879E37-F94D-4645-9965-3E5B0280A99DQ53331247-EE2302C1-69A1-482F-A572-4C995D3D86A3Q55258447-2EDDB97A-F174-4B6A-BA41-1797CEEDFCD8Q55382945-409BABB7-A6A2-4DAE-8CD9-C98BAE646B1EQ55432449-FB33AB94-7CD7-41F7-98BC-FC0B9D8A7036
P2860
Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Optimizing Treatment with TNF ...... evels and Antidrug Antibodies.
@en
type
label
Optimizing Treatment with TNF ...... evels and Antidrug Antibodies.
@en
prefLabel
Optimizing Treatment with TNF ...... evels and Antidrug Antibodies.
@en
P2093
P2860
P1476
Optimizing Treatment with TNF ...... Levels and Antidrug Antibodies
@en
P2093
Casper Steenholdt
Jørn Brynskov
Klaus Bendtzen
P2860
P304
P356
10.1097/MIB.0000000000000772
P577
2016-08-01T00:00:00Z